MD Anderson Survey Shows Faculty Dissatisfaction with Top Leaders 2

Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%

The Centers for Medicare & Medicaid Services is planning a 33.4% cut to the reimbursement payments hospitals receive for all drugs acquired through the 340B program, according to a draft guidance published on July 7.

July 24, 2026

Vol.52 No.29

By Sara Willa Ernst

Regulatory News

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings
Experts caution the move amounts to a “huge, unregulated, natural experiment”

In a video captioned “The High-T Department of War” and posted on X, Secretary of Defense Pete Hegseth announced that he was authorizing a screening program for troops to ensure “you have the right testosterone levels to operate at your absolute best.”

July 24, 2026

Vol.52 No.29

By Claire Marie Porter

Guest Editorial

The Susan Wojcicki Foundation pushes for rethinking of strategies for early lung cancer detection

The Susan Wojcicki Foundation, a new entrant into health philanthropy, is taking on a critical mission: Advancing research into new approaches to early detection of lung cancer—redefining risk, expanding awareness, and accelerating innovation.

Gary Morrow, a pioneer in supportive oncology, dies of prostate cancer complications at 82

Gary R. Morrow, PhD, MS, a longstanding leader at the University of Rochester Medicine Wilmot Cancer Institute and a visionary credited with building the science around easing cancer symptoms and side effects such as nausea, died on July 7 of pneumonia complications after coping with prostate cancer for 16 years. He was 82.

July 24, 2026

Vol.52 No.29

By Leslie Orr

Cancer Policy

China has outpaced the U.S. in novel cancer drug approvals since 2023, Friends analysis shows

China approved more novel oncology drugs than the United States from 2020 to 2025, according to a new analysis from Friends of Cancer Research  published in Health Affairs Scholar.

HHS defers more than $1B in Medicaid payments to California, Minnesota pending review of high-risk claims in crackdown on fraud

HHS and the Centers for Medicare & Medicaid Services deferred more than $1 billion in federal Medicaid payments to California and Minnesota as these states submit additional documentation supporting certain Medicaid claims.

July 24, 2026

Vol.52 No.29

By Jacquelyn Cobb

MD Anderson Survey Shows Faculty Dissatisfaction with Top Leaders 2

YOU MAY BE INTERESTED IN

Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings
Experts caution the move amounts to a “huge, unregulated, natural experiment”

The Susan Wojcicki Foundation pushes for rethinking of strategies for early lung cancer detection

Gary Morrow, a pioneer in supportive oncology, dies of prostate cancer complications at 82

China has outpaced the U.S. in novel cancer drug approvals since 2023, Friends analysis shows

HHS defers more than $1B in Medicaid payments to California, Minnesota pending review of high-risk claims in crackdown on fraud

Renew today!

Subscriber content

Never miss an issue!

Login

MD Anderson Survey Shows Faculty Dissatisfaction with Top Leaders 2

YOU MAY BE INTERESTED IN

Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warningsExperts caution the move amounts to a “huge, unregulated, natural experiment”

The Susan Wojcicki Foundation pushes for rethinking of strategies for early lung cancer detection

Gary Morrow, a pioneer in supportive oncology, dies of prostate cancer complications at 82

China has outpaced the U.S. in novel cancer drug approvals since 2023, Friends analysis shows

HHS defers more than $1B in Medicaid payments to California, Minnesota pending review of high-risk claims in crackdown on fraud

Never miss an issue!

Login

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings
Experts caution the move amounts to a “huge, unregulated, natural experiment”